Cargando…
Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T‐Cell Acute Lymphoblastic Leukemia
T‐cell acute lymphoblastic leukemia (T‐ALL) is an aggressive hematological malignancy with a poor prognosis, urging for novel therapeutic targets and treatment strategies. N6‐methyladenosine (m6A) is a crucial methylation modification that affects the pathogenesis of leukemia by regulating the mRNA...
Autores principales: | Zhou, Ying, Ji, Min, Xia, Yuan, Han, Xiaoyu, Li, Mingying, Li, Wei, Sun, Tao, Zhang, Jingru, Lu, Fei, Sun, Yanping, Liu, Na, Li, Jingxin, Ma, Daoxin, Ye, Jingjing, Ji, Chunyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839875/ https://www.ncbi.nlm.nih.gov/pubmed/36478193 http://dx.doi.org/10.1002/advs.202201724 |
Ejemplares similares
-
Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells
por: Zou, Jie, et al.
Publicado: (2013) -
Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia
por: Feng, Panpan, et al.
Publicado: (2022) -
NCBP1 enhanced proliferation of DLBCL cells via METTL3-mediated m6A modification of c-Myc
por: Meng, Sibo, et al.
Publicado: (2023) -
DEX‐Induced SREBF1 Promotes BMSCs Differentiation into Adipocytes to Attract and Protect Residual T‐Cell Acute Lymphoblastic Leukemia Cells After Chemotherapy
por: Jia, Ruinan, et al.
Publicado: (2023) -
Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy
por: Jia, Ruinan, et al.
Publicado: (2022)